Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer study aims to predict dangerous lung inflammation

NCT ID NCT06192004

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effect of cancer therapy. The study was observational, meaning no new treatment was given, and it was ended early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a digital tool that helps doctors identify lung cancer patients at risk of pneumonitis/ILD earlier.
What could go wrong
This study was terminated early with only 83 participants, so results may be limited. It is observational, not testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

83 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

NSCLC patients initiating an approved treatment with risk of pneumonitis/ILD; receiving SoC and initiating treatment with an FDA-approved immune checkpoint inhibitor (alone or in combination with other agents), antibody drug conjugate, or small molecule EGFR inhibitor.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient must be 18 years of age or older, at the time of signing the ICF (Informed consent). 2. Have histologically or cytologically documented unresectable Stage III or Stage IV NSCLC. 3. Are initiating treatment with an FDA (Food and Drug Administration)-approved immune checkpoint inhibitor (alone or in combination with other agents), antibody drug conjugate, or small molecule EGFR inhibitor. 4. Minimum life expectancy of 12 weeks at the time of signing the ICF. 5. Able and willing to provide written signed informed consent. 6. Able and willing to use the digital health tool throughout the duration of the study. Exclusion Criteria: 1. Concurrent participation in a research study or a clinical trial. 2. Unable to receive SoC for the treatment and management of NSCLC including clinical or imaging assessments for up to 6 months. 3. Judgment by the Investigator that the patient is unsuitable to participate in the study and/or the patient is unlikely to comply with study procedures and requirements. 4. Confirmed or suspected diagnosis of pneumonitis/ILD at the time of signing ICF. This does not apply to historical pneumonitis/ILD events that have resolved prior to signing ICF. 5. More than 2 weeks have passed from the administration of the first dose of qualifying FDA-approved treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease non-small cell lung carcinoma pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Research Site

    Los Angeles, California, 90027, United States

  • Research Site

    Los Angeles, California, 90033, United States

  • Research Site

    Denver, Colorado, 80204, United States

  • Research Site

    Golden, Colorado, 80222, United States

  • Research Site

    Miami Lakes, Florida, 33014, United States

  • Research Site

    Skokie, Illinois, 60076, United States

  • Research Site

    Ames, Iowa, 50010-3014, United States

  • Research Site

    Covington, Louisiana, 70433, United States

  • Research Site

    Troy, Michigan, 48098, United States

  • Research Site

    Florham Park, New Jersey, 07932, United States

  • Research Site

    Mickleton, New Jersey, 08056, United States

  • Research Site

    Shirley, New York, 11967, United States

  • Research Site

    Westbury, New York, 11590, United States

  • Research Site

    Canton, Ohio, 44708, United States

  • Research Site

    Canton, Ohio, 44710, United States

  • Research Site

    Cincinnati, Ohio, 45219, United States

  • Research Site

    Massillon, Ohio, 44646, United States

  • Research Site

    York, Pennsylvania, 17403, United States

  • Research Site

    Austin, Texas, 78745, United States

  • Research Site

    Dallas, Texas, 75246, United States

  • Research Site

    Houston, Texas, 77024, United States

  • Research Site

    Longview, Texas, 75601, United States

  • Research Site

    Odessa, Texas, 79902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.